Eltrombopag | Aplastic Anemia and MDS International Foundation

Eltrombopag

Eltrombopag (Promacta) is used to increase the number of platelets (cells that help blood clot) and to decrease the risk of bleeding. It is a man-made platelet growth factor that signals your bone marrow to make more platelets. Eltrombopag was approved by the U.S. Food and Drug Administration in 2014 to treat aplastic anemia. It comes as a tablet and as a powder for oral suspension (liquid) to take by mouth.
Brand name: 
Promacta
Bone Marrow Disease(s): 
aplastic anemia

What are the possible side effects of eltrombopag (Promacta)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.

Stop using eltrombopag and call your doctor at once if you have:

  • pain or burning when you urinate;
  • fever, chills, body aches, flu symptoms, unusual weakness or tired feeling;
  • nausea, upper stomach pain, itching, loss of appetite;
  • dark urine, clay-colored stools;
  • jaundice (yellowing of the skin or eyes);
  • pain, swelling, warmth, or redness in one or both legs;

Related Clinical Trials

AAMDSIF does not recommend, endorse, or make any representation about the efficacy, appropriateness or suitability of any drug, treatment or therapy listed on this website. Some therapies listed on our site are considered experimental for the treatment of bone marrow failure diseases. Always seek the advice of your physician or other qualified health care provider with any questions you may have regarding any therapy, and never disregard professional medical advice or delay in seeking it because of something you have read on this website.